Show simple item record

dc.contributor.advisorPeter Hutten_US
dc.contributor.authorFoster, Suzanne
dc.date.accessioned2012-05-19T21:56:02Z
dc.date.issued2009
dc.identifier.citationSuzanne Foster, FDA’s Position on Off-Label Use and Promotion of Drugs and Devices and Recent Enforcement Efforts by the Department of Justice (April 2009).en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8789612
dc.description.abstractOff-label drug or medical device “use” is the practice of prescribing drugs or medical devices to patients for a purpose not included on the federally approved label. Off-label “marketing” is the practice of attempting to influence physicians to prescribe drugs or devices for off-label purposes. The Federal Food and Drug Administration (FDA) maintains regulatory authority over the proper labeling of drugs and medical devices. This paper summarizes the FDA’s position on off-label use, promotion, and marketing and provides a summary of recent enforcement actions by the U.S. Department of Justice regarding off-label marketing.en_US
dash.licenseLAA
dc.subjecthuman drugs>>prescription drug promotion>>information on unapproved usesen_US
dc.subject.otherFood and Drug Lawen_US
dc.titleFDA’s Position on Off-Label Use and Promotion of Drugs and Devices and Recent Enforcement Efforts by the Department of Justiceen_US
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-05-19T21:56:02Z


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record